GO43878 - A Phase Iii, Open-Label, Multi-center Randomized Study Evaluating Glofitamab As A Single Agent Versus Investigator’s Choice In Patients With Relapsed/Refractory Mantle Cell Lymphoma (GLOBRYTE (GO43878))

Research summary

The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator’s choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) as measured by Blinded Independent Review Committee (BIRC) assessed progression-free survival (PFS). Participants will be randomized in a 1:1 ratio to receive either glofitamab as a single agent or an investigator’s choice between BR or R-Len. Approximately half of the patients on the control arm will receive BR therapy, the remaining patients will receive R-Len.

Principal Investigator

Dr Toby Eyre

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1008010